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Priming in response to pro-inflammatory
cytokines is a feature of adult synovial but
not dermal fibroblasts
Thomas Crowley1, John D. O’Neil1, Holly Adams1, Andrew M. Thomas2, Andrew Filer1, Christopher D. Buckley1
and Andrew R. Clark1*
Abstract
Background: It has been hypothesized that chronic inflammatory diseases such as rheumatoid arthritis (RA) may be
caused by a failure of negative feedback mechanisms. This study sought to examine negative feedback mechanisms in
fibroblast-like synoviocytes (FLS), one of the most abundant cell types in the joint. We hypothesized that prior
exposure of healthy FLS to an inflammatory stimulus would attenuate their responses to a second inflammatory
stimulus, in the same way that negative feedback mechanisms desensitize macrophages to repeated stimulation
by lipopolysaccharide. We further hypothesized that such negative feedback mechanisms would be defective in
FLS derived from the joints in RA.
Methods: Synovial fibroblasts and dermal fibroblasts from non-inflamed joints and joints affected by RA and a
fibroblast cell line from neonatal foreskin were stimulated twice with tumour necrosis factor (TNF) α or interleukin
(IL)-1α, with a 24-h rest period between the two 24-h stimulations. Differences between response to the first and
second dose of cytokine were examined by assessing secretion of inflammatory factors and intracellular signalling
activity.
Results: FLS from both non-inflamed joints and joints affected by RA mounted an augmented response to
re-stimulation. This response was site-specific, as primary dermal fibroblasts did not alter their response
between doses. The fibroblast priming was also gene-specific and transient. Assessment of signalling events
and nuclear localization showed prolonged activation of nuclear factor (NF)-κB during the second stimulation.
Conclusion: This study aimed to examine mechanisms of negative regulation of inflammatory responses in
FLS. Instead, we found a pro-inflammatory stromal memory in FLS obtained from both non-inflamed joints and
joints affected by RA. This suggests the joint is an area at high risk of chronic inflammation, and may provide a
piece in the puzzle of how chronic inflammation is established in RA.
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Background
Rheumatoid arthritis (RA), a chronic inflammatory disease
of the joint, is one of the most common autoimmune dis-
eases in the UK, affecting over 1% of the population [1].
In RA, high levels of pro-inflammatory cytokines are
maintained within the joint, chemokine gradients
continue to recruit leukocytes and the cells within the
synovium are retained and are prevented from undergoing
apoptosis. Further, the tissue-resident stromal cells be-
come hyperplastic, leading to the growth of an invasive
pannus, which narrows the joint space and degrades both
articular cartilage and bone.
One of the predominant cell types of the synovial
stroma is the fibroblast-like synoviocyte (FLS). It has
become increasingly apparent that the FLS is crucial to
normal and aberrant inflammatory responses in the joint
[2–4]. FLS can release large quantities of pro-inflammatory
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cytokines. IL-6, for example, is secreted at higher basal
levels in FLS in RA than in osteoarthritis (OA) [5]. FLS in
RA increase leukocyte adhesion to [6] and transmigration
through [7] endothelial layers, and the high concentration
of CXCL12 produced by FLS in RA restricts the egress of
leukocytes from the joint [8]. Further, FLS release of gran-
ulocyte macrophage colony stimulating factor (GMCSF)
keeps neutrophils alive for twice the normal span in vitro,
and this growth factor is produced at higher levels by FLS
in RA than in healthy controls [9–11]. FLS in patients with
RA have an increased rate of proliferation [12], are more
resistant to apoptosis than FLS in their healthy counter-
parts [13], and also have increased invasive capabilities and
matrix metalloproteinase (MMP) production [14]. Finally,
the strongest evidence for the pathogenic role of FLS in RA
comes from the experiments of Muller-Ladner et al., who
showed that FLS in RA could be cultured in vitro and
then implanted in mice with severe combined immuno-
deficiency (SCID) to induce RA-like disease in the ab-
sence of immune cells [15]. Thus, FLS in RA are now
viewed as “imprinted aggressors” rather than the trad-
itional “passive responders” [16].
It is well-known that inflammation does not passively
end, but is actively switched off [17–21]. It is therefore
possible that chronic inflammatory diseases such as RA
involve failure of mechanisms in the resolution of in-
flammation. The negative regulation of inflammation
has been well-characterised in monocytes/macrophages
(reviewed in [22]). Macrophages respond to a variety of
inflammatory stimuli, both endogenous, such as TNFα
and IL-1, and exogenous, such as lipopolysaccharide (LPS).
Whilst these stimuli elicit strong inflammatory responses,
they also induce anti-inflammatory pathways that curtail
macrophage inflammation [19, 22, 23]. Negative regulation
of inflammation occurs at a range of levels, both within
and without the cell. Pro-inflammatory stimuli often elicit
anti-inflammatory mechanisms to curtail their own action
[22]. This is exemplified by the nuclear factor (NF)-κB-
IκBα negative feedback loop. Once a stimulatory signal
causes degradation of its inhibitor IκBα, NF-κB is free to
translocate to the nucleus and facilitate transcription of
pro-inflammatory mediator genes. Another gene also
induced by NF-κB is NF-κB-inhibitor-α (Nfkbia), which
encodes IκBα. Nascent IκBα shuttles NF-κB out of the
nucleus to once again be held inactive, thereby curtail-
ing the transcriptional response to stimulus [24, 25].
Despite the abundant literature on negative regulation
of inflammation in macrophages, there is a comparative
paucity of information on fibroblasts. Evidence from Lee
et al. suggests that FLS in RA lack the inherent negative
regulation seen in macrophages [26]. Rather, FLS contin-
ued to produce pro inflammatory mediators for the dur-
ation of incubation with TNFα, even after four days of
stimulation. This paper also showed significantly lower
expression of negative regulators such as A20-binding in-
hibitor of NFκB activation 3 (ABIN3), activating tran-
scription factor 3 (ATF3), IL-1 receptor-associated kinase
M (IRAK-M), and suppressor of cytokines signalling 3
(SOCS3) in FLS in RA compared to macrophages. The
implication is that FLS are deficient in the negative feed-
back regulation of inflammation in RA. However, no com-
parison was made with FLS obtained from non-inflamed
joints. A similar study showed that gingival fibroblasts
(HGF) lack SOCS1, IRAKM and SH2 domain-containing
inositol phosphatase 1 (SHIP1) proteins, which are all
used in negative regulation of inflammation [27].
We sought to compare the inflammatory responses of
FLS obtained from inflamed (RA) and non-inflamed joints,
with the aim of elucidating which (if any) mechanisms are
used by FLS to limit their inflammatory responses, and to
test the hypothesis that such mechanism(s) would be aber-
rant or absent in FLS in RA. Experimental design has been
based upon the model of endotoxin tolerance in macro-
phages, which has been extensively used to elucidate mech-
anisms of negative regulation of inflammatory responses in
those cells [28–31]. Exposure of macrophages to a single
dose of LPS reprogrammes their responses to a second
dose, such that expression of pro-inflammatory mediators
is attenuated, whilst expression of anti-microbial products
is spared [30, 31]. In a similar fashion, we exposed fibro-
blasts to two doses of TNFα, with an intervening rest
period in the absence of the pro-inflammatory cytokine.
We then compared the first and second responses. Contra-
dictory to our initial hypothesis, we found FLS to augment
their cytokine-induced IL-6 secretion when primed with ei-
ther TNFα or IL-1α. We found this priming phenomenon
to occur in FLS derived from both inflamed and non-
inflamed joints, but not fibroblasts from adult skin. The
augmented second response was gene-specific and transi-
ent. Sustained activation of NF-κB in response to the sec-
ond stimulation may play a role in fibroblast priming.
Methods
Study participants
Patients with RA who were involved in this study were
diagnosed according to the 1987 American College of
Rheumatology (ACR) criteria [32]. Synovial tissue was
collected during joint replacement surgery. Ultrasound-
guided synovial biopsies were collected during arthro-
scopic examination of unexplained joint pain. Where
there was no evidence of inflammatory joint pathology,
and no diagnosis of RA was subsequently made, these
samples were designated as “healthy” (non-inflamed)
controls. Dermal fibroblasts were derived from skin sam-
ples collected at the time of joint replacement surgery in
patients with OA and from patients with RA. Synovial
and dermal fibroblasts were cultured as previously de-
scribed [9]. The study (National Research Ethics Service
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(NRES) Committee West Midlands - The Black Country
Ref. 07/H1204/191) and all participants in this study
gave written, informed consent.
Cells
Fibroblasts were isolated from synovium and skin as pre-
viously described [9]. Cells were grown in Roswell Park
Memorial Institute (RPMI) medium supplemented with
10% foetal calf serum, 0.81 ×minimum essential medium
(MEM) non-essential amino acids, 0.81 mM sodium
orthopyruvate, 1.62 mM glutamine, 810 U/mL penicillin
and 81 μg/mL streptomycin. Cells were used at passages
3–8. A dermal fibroblast line from neonatal foreskin, BJ
(ATCC CRL-2522), was purchased from ATCC. Cells were
grown in Eagle’s minimum essential medium (EMEM)
(ATCC) supplemented with 10% foetal calf serum, 810 U/mL
penicillin and 81 μg/mL streptomycin.
Experimental design
The repeat dose experiments involved seeding cells and
allowing them to adhere overnight, before stimulating
cells with vehicle (growth medium), TNFα at 10 ng/mL,
or IL-1α at 10 ng/mL (both Peprotech) for 24 h. Condi-
tioned medium was removed and cells were washed
thoroughly before being rested for one, three or seven
days in fresh medium. In some instances, cells were
treated with 100 nM MLN4924 or vehicle control (0.1%
dimethyl sulfoxide (DMSO)) during the first stimulation
with TNFα, or during the one-day rest period. Cells were
washed again after the rest period and stimulated with
vehicle, TNFα or IL-1α at the same concentration as
above. Conditioned medium was removed after 24 h for
analysis.
Assessment of NF-κB activity or localization was based
on cells seeded into 6-cm dishes for western blots, and
eight chamber glass slides for immunofluorescence stud-
ies. Cells were left overnight to adhere, and then stimu-
lated with TNFα (10 ng/mL) at the time points described
in the appropriate figures.
Analysis
Enzyme-linked immunosorbent assay (ELISA) was used to
measure the secretion of cytokines. IL-6 (cat #88-7066-88),
IL-8 (cat #88-8086-88), and CCL5 (cat #BMS-287/2INST)
ELISA kits were purchased from E Bioscience. The latter
was used according to manufacturer’s instructions, the two
former were used with a 1-ng/mL top standard, in order to
capture a greater range of responses to various stimuli.
Western blot analysis was conducted to assess internal
protein abundance and activation. BJ cells were lysed in
radioimmunoprecipitation assay (RIPA) buffer (150 mM
sodium chloride, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, 50 mM Tris pH8). Assessment of nuclear and
cytosolic protein localization was performed using a
hypotonic lysis buffer and centrifugation to isolate the
cytosolic fraction, and a nuclear extraction buffer and
centrifugation to isolate the nuclear fraction. Gel blotting
was performed using 12-well pre-cast gels and membranes
from BioRad. The following western blotting antibodies
were all from Cell Signaling Technology: α Tubulin,
Lamin A/C, phospho-p38 (T180/Y182), RelA, phospho-
RelA (S536), phospho-ERK (T202/Y204) and phospho-
JNK (T183/Y185). All antibodies were used at 1:1000
dilution in 5% BSA as blocking reagent, except α Tubulin
and RelA, which were at 1:2000 dilution in 5% milk.
Immunofluorescence
Cells on chamber slides were fixed using 4% paraformal-
dehyde for 20 minutes, washed three times for 5 minutes
in PBS, then permeabilized using 0.1% Triton for 2 mi-
nutes before repeat washing with PBS. Slides were then
blocked in 10% horse serum for 1 h. NF-κB cellular
localization was assessed using a RelA antibody (#H0714
Santa Cruz) used at 1:200 dilution in 1% horse serum
and incubated overnight in the dark at 4 °C. Slides were
then washed three times for 5 minutes and incubated
with a goat anti-rabbit IgG fluorescein isothiocyanate
(FITC)-conjugated antibody (#4050-02 Southern Biotech)
(1:200) in the dark for 1 h at room temperature. Slides
were then mounted in 1,4-diazabicyclo[2.2.2]octane
(DABCO) for microscopy analysis. Control chambers
received no primary antibody, but received secondary
antibody at the same concentration at stated above. As an
isotype control, FLS received FITC-conjugated rabbit IgG.
Cells were imaged on a Zeiss AxioCam ERc5s with sup-
porting Zen blue edition software.
Statistical analysis
Repeat dose data are represented either as raw values, or
as fold changes from response to the first dose, which is
normalised to one. Data are presented as mean with SEM
error bars. Comparison of the first and second response
to stimulus was conducted after normalisation. The
Wilcoxon signed rank test was used, and significance is
designated as p = 0.05 (*) or p = 0.01 (**). Comparison
of the first and second response at equivalent time
points was analysed by the Mann-Whitney U test, with
p = 0.05 (*). Statistical analyses were performed using
GraphPad Prism 6.0 (GraphPad Software).
Results
Response of primary human fibroblasts to repeated
stimulation with TNF
This study employed FLS from non-inflamed joints and
from joints affected by both early and late RA. Many of
these lines proliferated slowly and reached replicative
senescence after a few passages. It was discovered that
the rapidly dividing foreskin fibroblast line BJ behaved
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very similarly to FLS in terms of responses to re-
stimulation. BJ cells were used in some experiments re-
quiring large numbers of cells, and key findings were
validated using primary FLS.
BJ cells were used to investigate whether primary hu-
man fibroblasts could be tolerized to inflammatory stimuli
in the same manner that macrophages become tolerized
to LPS [30] (Fig. 1a). Fibroblasts were treated with or
without TNF for 24 h, supernatant was collected, cells
were washed and rested for a further 24 h, then washed
again and treated with or without TNF for a further 24 h.
In the absence of stimulus, low amounts of IL-6 were se-
creted during the first 24 h (Fig. 1b, column 1) or between
48 and 72 h (column 3). If cells were treated with TNF
during the first 24 h and then the stimulus was removed,
expression of IL-6 was also low between 48 and 72 h
(Fig. 1b, column 5), indicating that the continued presence
of TNF is necessary for maintaining an inflammatory re-
sponse. IL-6 expression was induced to a similar extent in
cells stimulated at 0 h and harvested at 24 h, or stimulated
for the first time at 48 h and harvested at 72 h (Fig. 1b,
columns 2 and 4). In contrast, cells that were exposed to
repeated TNF stimuli with an intervening 24-h rest period
expressed IL-6 at a significantly higher level (Fig. 1b,
column 6).
The TNFα-neutralizing antibody adalimumab was used
to test whether the augmented second response might be
caused by residual signalling of TNFα that had not been
effectively removed in the wash step (Fig. 1c): 1 μg/ml
adalimumab (Ad in Fig. 1) was sufficient to completely
block TNFα-induced IL-6 production (compare columns
2 and 3). However, the same concentration of adalimumab
during the rest period (24 to 48 h) had no impact on the
enhanced response to re-stimulation (compare columns 5
and 6). Prior exposure to TNF therefore primes BJ fibro-
blasts for an augmented response to re-stimulation with
the same cytokine. In subsequent figures, responses to
first and second stimulations are compared (equivalent to
Fig. 1b columns 2 and 6).
Priming of fibroblasts in response to pro-inflammatory
cytokines is site and gene specific, but not disease or
stimulus specific
RA-derived and non-inflamed control FLS were exposed
to repeat doses of TNF or IL-1α with an intervening
24-h rest period as described above, and release of IL-6
in response to the first and second stimulus was mea-
sured (Fig. 2). Although there was considerable variabil-
ity between individual FLS lines in terms of absolute
quantities of IL-6 produced, all showed robust increases
of IL-6 expression in response to both TNF and IL-1α.
Contrary to expectation, there were augmented re-
sponses to the second stimulus in almost all cases, and
it proved impossible to distinguish between FLS lines
Fig. 1 Pre-exposure of neonate dermal fibroblasts to TNF augments their
response to re-stimulation. a The experimental procedure. BJ fibroblasts
received vehicle or 10 ng/mL TNFα for 24 h, and were then washed
and rested for 24 h after collection of supernatants. Cells were then
washed again and treated with vehicle or 10 ng/mL TNFα for a further
24 h before collection of supernatants (Collect sup.). Stim stimulation, W
wash. b Fibroblast secretion of IL-6 in response to first or second doses
of vehicle or TNFα. c Fibroblast secretion of IL-6 under the same
conditions, with addition of 1 μg/mL adalimumab (Ad) either at
the same time as the first TNFα stimulus (third column) or during
the rest period between the first and second TNFα stimuli (sixth
column). Mean ± SEM, n = 3–6. **p < 0.01; ***p < 0.005; n.s. not
statistically significant
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on the basis of their origin in RA or non-inflamed
synovium. Synovial fibroblast priming in response to
pro-inflammatory cytokines, therefore, does not appear
to be a disease-specific phenomenon.
To test whether fibroblasts from a different anatomical
site also demonstrated priming in response to pro-
inflammatory stimuli, human dermal fibroblasts (HDFs)
were repeatedly stimulated with TNF or IL-1α as in
Fig. 1. It should be noted that HDFs were derived from
the skin of adults undergoing joint replacement, and
behave very differently from the BJ neonatal foreskin
fibroblasts investigated in Fig. 1. Expression of IL-6 was
induced by TNF or IL-1α in all HDF lines tested
(Fig. 3a). Responses to the first and second stimulus
were not significantly different. Unlike FLS or BJ cells,
dermal fibroblasts are not primed by prior exposure to
pro-inflammatory cytokines.
Priming was not stimulus-specific (Fig. 3b). BJ fibro-
blasts stimulated for 24 h with TNF and then rested for
24 h had augmented responses to re-stimulation with
either TNF or IL-1. Likewise, IL-1 effectively primed
fibroblasts to respond more strongly to re-challenge
with either IL-1 or TNF. The gene specificity of fibro-
blast priming was next investigated by measuring
expression of IL-6, IL-8 and CCL5 in response to the
first and second stimulation of FLS with TNF. Like
IL-6, the T cell chemokine CCL5 displayed an aug-
mented response to re-challenge with TNF (Fig. 3c),
whereas expression of IL-8, a neutrophil chemokine,
did not significantly differ in response to the first and
second stimulation. This gene specificity indicated
that FLS priming was unlikely to be explained trivially
by increased cell number during the rest period, or
by receptor sensitization.
Fibroblast priming is transient, and accompanied by
changes in cytokine-induced intracellular signaling
To investigate the duration of fibroblast priming by pro-
inflammatory cytokine, we conducted the repeat dose
experiment on FLS but lengthened the rest period be-
tween stimulations (Fig. 4a). The FLS used in these experi-
ments were derived from both RA and non-inflamed
joints, which did not significantly differ in their actions
(not shown). There was inverse correlation between the
Fig. 2 Fibroblast-like synoviocytes (FLS) are primed by pro-inflammatory cytokines whether they are derived from inflamed or non-inflamed joints.
FLS were stimulated (stim) for 24 h with either TNFα or IL-1α (10 ng/mL) before the stimulus was removed and cells were rested in fresh medium
for 24 h. Cells were then washed and stimulated with 10 ng/mL of the same cytokine for a further 24 h. IL-6 secretion in response to the first and
second dose was measured by ELISA. a Absolute concentrations of IL-6 in supernatants after the first and second exposure to TNFα (left) or IL-1α
(right). b IL-6 secretion in response to the second dose, represented as a fold change from the response to the first dose (normalised to 1); n = 10
(5 from non-inflamed joints, 5 from joints affected by rheumatoid arthritis (RA)). Grey circles and connecting lines represent FLS from joints affected
by RA. Black crosses and connecting lines represent FLS from non-inflamed joints. *p < 0.05; **p < 0.01 (Wilcoxon matched pair signed rank test)
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length of the rest period and the magnitude of the second
response. The priming effect of TNF (fold difference be-
tween the second and first response) was 3.41 after one
day of rest (p = 0.002), 2.62 after three days of rest (p =
0.031) and 1.81 after seven days of rest (not significant).
The priming effect of IL-1 also declined from one day of
rest, becoming statistically insignificant thereafter. There-
fore pro-inflammatory cytokine priming does not induce a
permanent change in the responsiveness of FLS.
The activation of NF-κB and mitogen-activated protein
kinase (MAPK) signalling pathways by pro-inflammatory
cytokines was relatively prolonged in BJ cells, remaining
significantly above basal levels even 24 h after addition
of stimulus (Fig. 4b, c). It was therefore speculated that
priming might reflect residual activity of pro-inflammatory
signalling pathways after withdrawal of the stimulus, grad-
ually declining during the rest interval. However, activation
of NF-κB, extracellular signal-related kinase (ERK), c-Jun
N-terminal kinase (JNK) and MAPK p38 all declined to
basal levels within 24 h of withdrawal of the cytokine
stimulus (Fig. 4b, c). There was no difference in resting
NF-κB or MAPK activity between cells rested for one
day or for three days after withdrawal of TNF. The re-
sponses of the same signalling pathways to the first and
second stimulation were then assessed. The activation
of MAPKs in response to a second challenge with TNF
was consistently attenuated (Fig. 5), an effect that was
particularly evident in the cases of ERK and JNK. The
first stimulation with TNF induced transient phosphoryl-
ation of the NF-κB subunit RelA at serine 536, a post-
translational modification associated with NF-κB activation.
In contrast the phosphorylation of Ser 536 in response to a
second TNF challenge was prolonged.
The duration of TNFα-induced NF-κB signaling was
further investigated by immunofluorescence microscopy
in RA FLS. RelA was mostly cytoplasmic prior to the
first stimulus (Fig. 6, top left). Discrete nuclear staining
was observed 30 and 120 minutes after addition of
TNFα, but by 240 minutes RelA was more broadly dis-
tributed or localized to the cytoplasm. Prior to the sec-
ond stimulus, strong staining for RelA was observed in
the nuclei of a few cells (Fig. 6, bottom left). Distinct nu-
clear staining was seen in the majority of cells at 30,
120 minutes and 240 minutes. Corresponding images
with nuclear 4′,6-diamidino-2-phenylindole (DAPI) stain
are shown in Additional file 1: Figure S1.
Similarly prolonged accumulation of nuclear RelA in
response to re-stimulation of BJ cells was confirmed by
immunofluorescence microscopy (Fig. 7a) and cell frac-
tionation (Fig. 7b, c). To investigate the significance of
prolonged NF-κB activation, BJ cells were stimulated or
re-stimulated with TNFα, and the NF-κB inhibitor
MLN4924 [33] or vehicle control was added after 2 h
(Fig. 7d). IL-6 biosynthesis in response to the first TNFα
stimulus did not increase strongly between 2 h and 8 h,
and was not significantly impaired by addition of
MLN4924 at 2 h. In contrast, IL-6 biosynthesis in re-
sponse to the second TNFα stimulus increased markedly
between 2 h and 8 h, and this increase was prevented by
MLN4924. These data suggest that prolonged NF-κB
signalling beyond the 2-h time point contributes to the
enhanced expression of IL-6 after re-stimulation.
Discussion
LPS tolerance involves a range of epigenetic and signalling
mechanisms that extensively reprogramme the responses
Fig. 3 Priming of fibroblasts by pro-inflammatory cytokines is site-specific and gene-specific, but not stimulus-specific. a Following the protocol
described in Fig. 1, primary human dermal fibroblasts were treated for 24 h with vehicle, TNFα or IL-1α, washed and rested for 24 h, then treated
again with vehicle, TNFα or IL-1α for 24 h. Expression of IL-6 protein was measured after the first and second treatments. Mean ± SEM, n = 5. n.s.
not significant as determined by the Mann-Whitney U test. b Adapting the protocol described in Fig. 1, BJ fibroblasts were treated for 24 h with
TNFα, washed and rested for 24 h then treated with TNFα or IL-1α for 24 h (left graph); or treated for 24 h with IL-1α, washed and rested for 24 h,
then treated with IL-1α or TNFα (right graph). IL-6 expression in response to the second stimulus is represented relative to the response to the
same first stimulus. Mean fold change in IL-6 expression between the second and first response ± SEM, n = 6. *p < 0.05 (Wilcoxon matched pair
signed rank test). c Fibroblast-like synoviocytes (FLS) were treated with TNFα for 24 h, washed and rested for 24 h, then re-stimulated with TNFα.
Secreted IL-6, CCL5 and IL-8 were measured after the first and second stimulations, and fold changes in expression calculated. Mean fold change ± SEM,
n = 5–8. **p< 0.01; n.s. not statistically significant (Wilcoxon matched pair signed rank test)
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of macrophages to re-stimulation, suppressing the induc-
tion of overtly pro-inflammatory genes whilst sparing
those with anti-microbial properties [28–31]. This may be
viewed as a form of innate immune memory that guards
against excessive inflammation without compromising de-
fence against pathogens. The present study was devised to
identify equivalent negative regulatory mechanisms by
which synovial fibroblasts constrain their responses to re-
peated pro-inflammatory challenge. Surprisingly, we in-
stead found that synovial fibroblasts were primed by a
first exposure to either TNFα or IL-1α, such that they se-
creted significantly greater amounts of IL-6 when chal-
lenged a second time, after a 24-h rest period.
Fibroblasts derived from RA synovium retain an
imprinted, invasive phenotype throughout prolonged cul-
ture in vitro [15, 16, 34]. Nevertheless, we found no
Fig. 4 Fibroblast priming is transient. a Fibroblast-like synovioctyes
(FLS) were stimulated (stim) with TNFα or IL-1α (both 10 ng/mL) for
24 h, washed and rested for one, three or seven days, then washed
and stimulated again for 24 h. Responses to the first and second
dose were analysed by IL-6 ELISA, and response to the second dose
was represented as a fold change from response to first dose
(normalised to one). Mean ± SEM, n = 5–10. *p < 0.05, **p < 0.01
(Wilcoxon matched pairs signed rank test); n.s. not significant b BJ
fibroblasts were treated with vehicle or TNFα for 24 h then washed
and rested in fresh medium for one, two or three days. Whole cell
lysates were prepared, and phosphorylated forms of signalling
molecules were detected by western blotting. c Phospho-RelA was
quantified in three independent experiments, normalized against
the loading control tubulin and plotted relative to the level in
unstimulated cells
Fig. 5 Fibroblast priming is accompanied by changes in signalling
responses to TNF. BJ fibroblasts were treated for varying times with
TNFα (10 ng/mL) with or without a prior 24 h exposure to TNFα and
24 h rest. Cell lysates were prepared and phosphorylated signalling
proteins were detected by western blotting. Results are representative
of five independent experiments. Vertical lines separate sections from
the same gel and exposure. ERK extracellular signal-related kinase, JNK
c-Jun N-terminal kinase
Crowley et al. Arthritis Research & Therapy  (2017) 19:35 Page 7 of 11
evidence that the priming phenomenon was specific to
RA-derived synovial fibroblasts. Similar priming responses
were demonstrated by synovial fibroblasts from ostensibly
healthy, non-inflamed joints of patients who did not have
RA, and who did not later develop RA. A neonatal fore-
skin fibroblast line was primed by TNFα or IL-1α in a
manner very similar to synovial fibroblasts, and was used
in this study as a tool to explore mechanisms. In contrast,
adult dermal fibroblasts (obtained from patients with OA
and patients with RA at the time of joint surgery) showed
no evidence of priming.
Synovial fibroblasts from joints affected by RA were
previously shown to mount unremitting inflammatory
responses, continuing to express IL-6 and other inflam-
matory mediators for at least four days in the presence
of TNFα [26]. The same group also demonstrated prim-
ing by TNFα of synovial fibroblasts in RA, resulting in
enhanced responses to later challenge with interferons
[35]. In those studies no comparison was made with
“normal” synovial fibroblasts. It is therefore possible that
the properties described are characteristic of synovial
fibroblasts as a whole, rather than acquired during the
pathogenesis of RA. It is not a novel concept that fibro-
blasts differ in their patterns of gene expression and re-
sponse to stimulation, according to the anatomical
location from which they are obtained [11, 36–38]. The
important questions are why synovial fibroblasts should
possess “inflammatory memory” [35], and whether such
memory could play a role in the development of chronic
joint disease.
One argument is that fibroblast responses to pro-
inflammatory stimuli are dictated by their usual pat-
tern of exposure to such stimuli [27]. In mucosal or
dermal fibroblasts that are repeatedly exposed to pro-
inflammatory insults, priming responses would be severely
maladaptive. In contrast, fibroblasts from privileged sites
such as the joint or the eye presumably seldom face
sustained or repeated exposure to pro-inflammatory cy-
tokines in healthy individuals, and may have evolved
different responses to such danger signals. This hypoth-
esis will be tested by investigating priming responses of
fibroblasts from different anatomical locations of
healthy and diseased individuals. Another possibility is
suggested by the apparently gene-specific nature of the
phenomenon, in which primed responses of IL-6 and
CCL5 were enhanced, whereas that of IL-8 was not.
Perhaps, as an inflammatory response evolves, differen-
tial priming allows the stroma to influence leukocyte
recruitment and activation by modifying the profile of
cytokines and chemokines expressed. This possibility is
also under investigation.
Finally, the molecular basis of synovial fibroblast prim-
ing remains unknown. Increased expression of cytokine
receptors is unlikely to provide an explanation, because
of the gene-specific and signaling-pathway-specific effects
described. Sustained activation of NF-κB has been impli-
cated in the unremitting inflammatory response of syn-
ovial fibroblasts to prolonged TNFα exposure in RA [26].
Although we found NF-κB activity to decline after with-
drawal of TNFα, the dynamics of activation in response to
Fig. 6 Re-stimulation of fibroblast-like synoviocytes (FLS) with TNFα induces prolonged nuclear localization of RelA. FLS were seeded onto chamber
slides and stimulated (stim) with 10 ng/mL TNFα for the times indicated (upper images), or stimulated with TNFα for 24 h, washed and rested for 24 h,
then re-stimulated for the times indicated (lower images). RelA was detected by immunfluorescence microscopy. The far right images in each
row indicate isotype controls for the primary antibody, with 4′,6-diamidino-2-phenylindole (DAPI) staining of nuclei shown in red. Combined
RelA and DAPI images are shown in Additional file 1: Figure S1. Images are representative of four experiments using different FLS lines from
rheumatoid arthritis
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the second challenge were altered, with sustained nuclear
localization of the RelA subunit and phosphorylation of
its serine 536. It appears that the first exposure of FLS to
TNFα induces a transient burst of IL6 gene expression,
whereas the second exposure induces more sustained ex-
pression, dependent on prolonged activation of NF-κB.
We speculate that priming influences the expression or
function of negative feedback regulators required for the
termination of the NF-κB activation signal.
Conclusion
We demonstrated here that inflammatory memory is a
general property of synovial fibroblasts rather than a
peculiarity of synovial fibroblasts in RA. We show that
this phenomenon is transient, gene-specific rather than
universal, and is accompanied by alterations of cytokine-
induced signal transduction pathways. We hypothesize
that the propensity of synovial fibroblasts to respond
more strongly to re-stimulation contributes to the devel-
opment of chronic joint inflammation.
Additional file
Additional file 1: Figure S1. Re-stimulation of FLS with TNFα induces
prolonged nuclear localization of RelA. FLS were seeded onto chamber
slides and stimulated with 10 ng/mL TNFα for the times indicated
Fig. 7 Prolonged nuclear factor (NF)-κB activation in re-stimulated BJ cells contributes to enhanced IL-6 biosynthesis. a BJ fibroblasts were seeded
on chamber slides and stimulated with TNFα (10 ng/mL) for varying times, with or without prior exposure to TNFα for 24 h and rest in the absence of
TNFα for 24 h. RelA was detected by immunofluourescence. Images are representative of two independent experiments. White arrows indicate cells in
which RelA is principally nuclear. b BJ fibroblasts were untreated or stimulated (stim) with TNFα (10 ng/mL) for 2 h, with or without priming as above.
Nuclear (N) and cytoplasmic (C) fractions were prepared and RelA was detected by western blotting. Lamin A/C and tubulin were blotted in order to
validate the subcellular fractions. Results are representative of four independent experiments. c Nuclear RelA was quantified, normalised against the
Lamin A/C loading control, and plotted relative to the level at t = 0 in the first TNFα challenge. Mean ± SEM, n = 4; *p < 0.05 (Mann-Whitney U test).
d BJ fibroblasts were stimulated (left) or re-stimulated (right) with 10 ng/mL of TNFα, and 100 nM MLN4924 or vehicle control (0.1% dimethyl sulfoxide
(DMSO)) was added after 2 h. Supernatants were collected at the time points indicated, and IL-6 measured by ELISA; n = 6; *p < 0.05, ***p < 0.005;
Student t test
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(upper images), or stimulated with TNFα for 24 h, washed and rested for
24 h, then re-stimulated for the times indicated (lower images). Cells
were stained with DAPI to identify nuclei, and RelA was detected by
immunofluorescence microscopy. The same images without DAPI stain
are shown in Fig. 6 (TIF 11558 kb)
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